Aprea Therapeutics receives FDA clearance to initiate Phase 1 study of APR-548


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Aprea Therapeutics receives FDA clearance to initiate Phase 1 study of APR-548
Karolinska Development's portfolio company Aprea Therapeutics receives FDA clearance to initiate Phase 1 study of APR-548

Karolinska Development AB announces that the US Food and Drug Administration (FDA) has accepted the portfolio company Aprea Therapeutics Investigational New Drug (IND) application regarding its new drug candidate APR-548 for the treatment of TP53- mutant myelodysplastic syndrome (MDS). APR-548 is a next generation reactivator of mutated p53 and is being developed for oral administration.

Aprea Therapeutics intends to initiate a Phase 1 clinical trial with APR-548 in MDS to strengthen its leading position in the development of therapeutic options for patients with p53 mutated cancer. In parallel with this, a registration-based phase 3 study is underway with the company's most advanced p53 reactivator, eprenatapopt (APR-246), with expected top line results at the end of 2020.

APR-548 has shown high oral bioavailability, improved potency over eprenetapopt in TP53 mutant cancer cell lines and in vivo tumour growth inhibition after oral dosing in tumour-bearing mice.

Karolinska Development AB is a Nordic investment company in life science. The company focuses on identifying medical innovations and investing to create and develop companies that further develop such innovations into differentiated products that can make a difference to patients' lives and generate an attractive return for shareholders.

Karolinska Development has access to world-class medical research from Karolinska Institutet and other leading universities and research institutions in the Nordic region. The company's goal is to build companies around researchers who are leaders in their respective fields of science, with support from experienced management teams and advisers, and with funding together with international investors who specialize in the sector. To create the best opportunities for success, companies are built with experienced management advisors and they are co-financed by professional life science investors.

Karolinska Development's portfolio consists of ten companies focused on developing innovative treatment methods for diseases that are life-threatening or disabling and other medical conditions.

Tags : #KarolinskaDevelopment #ApreaTherapeutics #LatestPharmaNews0810 #LatestReceivedUSFDAClearance0810 #LatestCancerTreatment

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026